Clinical evaluation of subcutaneously administered DDAVP

Area of Science:

• Hematology
• Pharmacology

Background:

• Mild factor VIII deficiencies, including hemophilia A and von Willebrand Disease, present challenges in bleeding management.
• Effective and accessible treatment options are crucial for patients experiencing spontaneous or procedure-related hemorrhages.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous 1-deamino-8D-arginine vasopressin (DDAVP) in patients with mild factor VIII deficiencies.
• To assess DDAVP's utility for treating acute bleeding episodes and preventing hemorrhage during surgical and dental procedures.

Main Methods:

• A subcutaneous dosage of 0.3 micrograms/Kg body weight of DDAVP was administered to 24 patients with mild factor VIII deficiencies.
• Treatment was provided for acute bleeding episodes (n=10), dental extractions (n=6), and surgical interventions (n=11).
• Patients with spontaneous bleeding episodes were instructed in self-administration for home treatment.

Main Results:

• No bleeding complications were observed in patients undergoing surgery.
• DDAVP demonstrated effectiveness in the early management of muscle hematomas and cessation of mucosal hemorrhages.
• The drug was administered in two concentrations (4 and 40 micrograms/ml) with no discernible difference in clinical outcomes.
• No significant adverse events were reported during the study.

Conclusions:

• Subcutaneous DDAVP is a safe and effective therapeutic option for managing bleeding in mild factor VIII deficiencies.
• The concentrated pharmaceutical form is particularly useful for self- and home-treatment by patients.
• DDAVP offers a valuable treatment strategy for both acute bleeding and prophylaxis in specific patient populations.